Proactive and Reactive Therapeutic Drug Monitoring of Biologic Therapies in Inflammatory Bowel Disease Are Complementary, Not Mutually Exclusive

Biologic pharmaceuticals such as tumor necrosis factor (TNF) inhibitors are cornerstones in the treatment of moderate-to-severe inflammatory bowel disease (IBD), and are used to both dampen or even reverse active disease during flares and to maintain quiescent disease once attained. Therapeutic drug monitoring (TDM), whereby measurements of anti-TNF drug levels and antibodies (Abs) against the TNF inhibitor are used to tailor therapies, has gained momentum because, at least theoretically, it offers benefits over standardized dosings and administration intervals.

http://ift.tt/2G26OXT